Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age.
Title | Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Iosifidis, E., Chorafa E., Agakidou E., Kontou A., Violaki A., Volakli E., Christou E-I., Zarras C., Drossou-Agakidou V., Sdougka M., & Roilides E. |
Journal | Pediatr Infect Dis J |
Volume | 38 |
Issue | 8 |
Pagination | 812-815 |
Date Published | 2019 08 |
ISSN | 1532-0987 |
Keywords | Age Factors, Anti-Bacterial Agents, Azabicyclo Compounds, Ceftazidime, Child, Preschool, Cross Infection, Drug Combinations, Drug Resistance, Multiple, Bacterial, Female, Humans, Infant, Infant, Newborn, Klebsiella Infections, Klebsiella pneumoniae, Male, Microbial Sensitivity Tests, Retrospective Studies, Severity of Illness Index, Treatment Outcome |
Abstract | BACKGROUND: Emergence of extensively drug-resistant (XDR) or pan drug-resistant (PDR) Enterobacteriaceae is a major public threat especially for young patients. Treatment options for these bacteria are extremely limited with no safety data existing for neonates and children. Ceftazidime-avibactam has activity against Gram-negative bacteria producing Klebsiella pneumoniae carbapenemase, but virtually no data exist on its use in neonatal and pediatric patients. |
DOI | 10.1097/INF.0000000000002344 |
Alternate Journal | Pediatr Infect Dis J |
PubMed ID | 31135647 |